Norgine today announced that the Australian assessment body the Pharmaceutical Benefits Advisory Committee has recommended the use of XIFAXAN 550 mg in the prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated; a potentially life-threatening neuropsychiatric condition associated with liver disease.
[More]
By discovering the new mechanism by which estrogen suppresses lipid synthesis in the liver, UC Irvine endocrinologists have revealed a potential new approach toward treating certain liver diseases.
[More]
Viral hepatitis is an asymptomatic disease affecting more than 5.3 million Americans. More than 75 percent of those with hepatitis C are unaware they have the virus.
[More]
If you're a baby boomer, you may not know that odds are high that you're carrying the hepatitis C virus, putting yourself at risk for illness that can range from minor to life threatening.
[More]
In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis bacteria in laboratory culture.
[More]
Research presented today at Digestive Disease Week explores new discoveries in liver disease research, with findings about the impact of coffee on autoimmune disease and palliative care for cirrhotic patients.
[More]
An increasing number of U.S. children are experiencing gastrointestinal issues that require interventions to resolve, according to research presented at Digestive Disease Week.
[More]
In order to avoid harms associated with alcohol consumption, in 2009 the National Institute on Alcohol Abuse and Alcoholism issued guidelines that define low-risk drinking. These guidelines differ for men and women: no more than four drinks per day, and 14 drinks per week for men, and no more than three drinks per day, and seven drinks per week for women.
[More]
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has presented key pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 (ALAS-1) for the treatment of porphyria including acute intermittent porphyria.
[More]
In the past 30 years the number of children living in the U.S. who are obese has more than doubled and the number of adolescents has tripled. In response, Loyola University Health System has created a Pediatric Weight Management Program designed to help families and communities in the fight against this epidemic.
[More]
Northwest Biotherapeutics, a biotechnology company developing DCVax-L personalized immune therapies for solid tumor cancers, today announced that its Phase III clinical trial with DCVax-L for brain cancer has been initiated at King's College Hospital in the UK.
[More]
PENTAX Medical Company, a healthcare industry leader in endoscopic imaging, announces the U.S. launch of the EPK-i5010 Video Processor with PENTAX i-SCAN™, the industry's highest resolution HD+ imaging technology for flexible endoscopy.
[More]
PENTAX Medical Company, a healthcare industry leader in endoscopic imaging, announces the U.S. launch of the EPK-i®5010 Video Processor with PENTAX i-SCAN™, the industry's highest* resolution HD+ imaging technology for flexible endoscopy.
[More]
Medivir AB today announces that the U.S. Food and Drug Administration has granted Priority Review to the New Drug Application by Janssen for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.
[More]
People with higher levels of cadmium in their urine — evidence of chronic exposure to the heavy metal found in industrial emissions and tobacco smoke — appear to be nearly 3.5 times more likely to die of liver disease than those with lower levels, according to a study by Johns Hopkins scientists.
[More]
A group of 40 students are part of Saint Louis University's Student National Medical Association chapter (SNMA), who are striving to reduce health disparities locally. This year, they received the Leadership in Institutional Diversity Award, a recognition given to a university for serving as an outstanding example of leadership and innovation in promoting and maintaining institutional diversity.
[More]
Cancer chemotherapy can cause peripheral neuropathy-nerve damage often resulting in pain and muscle weakness in the arms and legs. Now, researchers at Albert Einstein College of Medicine of Yeshiva University have discovered that chemo also induces an insidious type of nerve damage inside bone marrow that can cause delays in recovery after bone marrow transplantation.
[More]
Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough.
[More]
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved a supplemental new drug application for SUSTIVA (efavirenz), including dosing recommendations for HIV-1 infected pediatric patients three months to three years old and weighing at least 3.5 kg.
[More]
Martindale Pharma, a leader in the manufacture and supply of specialty pharmaceuticals, is pleased to announce the UK launch of Prenoxad Injection, the world's first licensed emergency treatment for acute opioid related overdose for use at home or other non-medical settings.
[More]